Factor VIII and von Willebrand factor - too sweet for their own good

Haemophilia

Volumn 16, Issue SUPPL. 5, 2010, Pages 194-199

  Lenting, P J ^a   Pegon, J N ^a   Christophe, O D ^a   Denis, C V ^a  

^a INSERM   (France)

Author keywords

Factor VIII; Glycosylation; Von Willebrand factor

Indexed keywords

BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 9; CARBOHYDRATE BINDING PROTEIN; CELL SURFACE RECEPTOR; GALECTIN; GLYCAN; RECOMBINANT BLOOD CLOTTING FACTOR 8; SIALIC ACID; SIALIC ACID BINDING IMMUNOGLOBULIN LIKE LECTIN 5; SIALIC ACID BINDING IMMUNOGLOBULIN LIKE LECTIN 7; SIALIC ACID BINDING IMMUNOGLOBULIN LIKE LECTIN 9; UNCLASSIFIED DRUG; VON WILLEBRAND FACTOR;

CARBOHYDRATE ANALYSIS; HUMAN; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN GLYCOSYLATION; PROTEIN INTERACTION; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; PROTEIN SYNTHESIS; REVIEW; THROMBOCYTE;

AMINO ACID SEQUENCE; FACTOR VIII; GLYCOSYLATION; HUMANS; POLYSACCHARIDES; PROTEIN STRUCTURE, TERTIARY; VON WILLEBRAND DISEASES; VON WILLEBRAND FACTOR;

EID: 77955035693     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/j.1365-2516.2010.02320.x     Document Type: Review

References (44)

1. Hironaka T, Furukawa K, Esmon PC. Comparative study of the sugar chains of factor VIII purified from human plasma and from the culture media of recombinant baby hamster kidney cells. J Biol Chem 1992, 267:8012-20.
2. Schilow WF, Schoerner-Burkhardt E, Seitz R. Charge analysis of N-glycans from human recombinant coagulation factor VIII and human FVIII standards. Thromb Haemost 2004, 92:427-8.
3. Kaufman RJ, Wasley LC, Dorner AJ. Synthesis, processing, and secretion of recombinant human factor VIII expressed in mammalian cells. J Biol Chem 1988, 263:6352-62.
4. Mazsaroff I, Yu W, Kelley BD, Vath JE. Quantitative comparison of global carbohydrate structures of glycoproteins using LC-MS and in-source fragmentation. Anal Chem 1997, 69:2517-24.
5. Thim L, Vandahl B, Karlsson J. Purification and characterization of a new recombinant factor VIII (N8). Haemophilia 2010, 16:349-359.
6. Varki A. Multiple changes in sialic acid biology during human evolution. Glycoconj J 2009, 26:231-45.
7. Chung CH, Mirakhur B, Chan E. Cetuximab-induced anaphylaxis and IgE specific for galactose-alpha-1,3-galactose. N Engl J Med 2008, 358:1109-17.
8. Pipe SW. Functional roles of the factor VIII B domain. Haemophilia 2009, 15:1187-96.
9. Pipe SW, Morris JA, Shah J, Kaufman RJ. Differential interaction of coagulation factor VIII and factor V with protein chaperones calnexin and calreticulin. J Biol Chem 1998, 273:8537-44.
10. Moussalli M, Pipe SW, Hauri HP, Nichols WC, Ginsburg D, Kaufman RJ. Mannose-dependent endoplasmic reticulum (ER)-Golgi intermediate compartment-53-mediated ER to Golgi trafficking of coagulation factors V and VIII. J Biol Chem 1999, 274:32539-42.
11. Zhang B, Kaufman RJ, Ginsburg D. LMAN1 and MCFD2 form a cargo receptor complex and interact with coagulation factor VIII in the early secretory pathway. J Biol Chem 2005, 280:25881-6.
12. Zhang B, Cunningham MA, Nichols WC. Bleeding due to disruption of a cargo-specific ER-to-Golgi transport complex. Nat Genet 2003, 34:220-5.
13. Bovenschen N, Rijken DC, Havekes LM, van Vlijmen BJ, Mertens K. The B domain of coagulation factor VIII interacts with the asialoglycoprotein receptor. J Thromb Haemost 2005, 3:1257-65.
14. Lee YC, Townsend RR, Hardy MR. Binding of synthetic oligosaccharides to the hepatic Gal/GalNAc lectin. Dependence on fine structural features. J Biol Chem 1983, 258:199-202.
15. Dasgupta S, Navarrete AM, Bayry J. A role for exposed mannosylations in presentation of human therapeutic self-proteins to CD4+ T lymphocytes. Proc Natl Acad Sci USA 2007, 104:8965-70.
16. Medzihradszky KF, Besman MJ, Burlingame AL. Structural characterization of site-specific N-glycosylation of recombinant human factor VIII by reversed-phase high-performance liquid chromatography-electrospray ionization mass spectrometry. Anal Chem 1997, 69:3986-94.
17. Matsui T, Titani K, Mizuochi T. Structures of the asparagine-linked oligosaccharide chains of human von Willebrand factor. Occurrence of blood group A, B, and H(O) structures. J Biol Chem 1992, 267:8723-31.
18. Sodetz JM, Paulson JC, McKee PA. Carbohydrate composition and identification of blood group A, B, and H oligosaccharide structures on human Factor VIII/von Willebrand factor. J Biol Chem 1979, 254:10754-60.
19. Turecek PL, Mitterer A, Matthiessen HP. Development of a plasma- and albumin-free recombinant von Willebrand factor. Hamostaseologie 2009, 1:S32-8.
20. Samor B, Michalski JC, Mazurier C. Primary structure of the major O-glycosidically linked carbohydrate unit of human von Willebrand factor. Glycoconj J 1989, 6:263-70.
21. Canis K, McKinnon TA, Nowak A. The plasma von Willebrand factor O-glycome comprises a surprising variety of structures including ABH antigens and disialosyl motifs. J Thromb Haemost 2010, 8:137-45.
22. Wagner DD, Mayadas T, Marder VJ. Initial glycosylation and acidic pH in the Golgi apparatus are required for multimerization of von Willebrand factor. J Cell Biol 1986, 102:1320-4.
23. Carew JA, Quinn SM, Stoddart JH, Lynch DC. O-linked carbohydrate of recombinant von Willebrand factor influences ristocetin-induced binding to platelet glycoprotein 1b. J Clin Invest 1992, 90:2258-67.
24. Millar CM, Brown SA. Oligosaccharide structures of von Willebrand factor and their potential role in von Willebrand disease. Blood Rev 2006, 20:83-92.
25. Federici AB, De RC, De Groot PG. Adhesive properties of the carbohydrate-modified von Willebrand factor (CHO-vWF). Blood 1988, 71:947-52.
26. Bastida E, Monteagudo J, Ordinas A, De ML, Castillo R. Asialo von Willebrand factor enhances platelet adhesion to vessel subendothelium. Thromb Haemost 1988, 60:30-4.
27. Lopes AA, Ferraz de Souza B, Maeda NY. Decreased sialic acid content of plasma von Willebrand factor in precapillary pulmonary hypertension. Thromb Haemost 2000, 83:683-7.
28. Grewal PK, Uchiyama S, Ditto D. The Ashwell receptor mitigates the lethal coagulopathy of sepsis. Nat Med 2008, 14:648-55.
29. Ellies LG, Ditto D, Levy GG. Sialyltransferase ST3Gal-IV operates as a dominant modifier of hemostasis by concealing asialoglycoprotein receptor ligands. Proc Natl Acad Sci USA 2002, 99:10042-7.
30. Mohlke KL, Purkayastha AA, Westrick RJ. Mvwf, a dominant modifier of murine von Willebrand factor, results from altered lineage-specific expression of a glycosyltransferase. Cell 1999, 96:111-20.
31. Federici AB, Elder JH, De ML, Ruggeri ZM, Zimmerman TS. Carbohydrate moiety of von Willebrand factor is not necessary for maintaining multimeric structure and ristocetin cofactor activity but protects from proteolytic degradation. J Clin Invest 1984, 74:2049-55.
32. McGrath RT, McKinnon TA, Byrne B. Expression of terminal {alpha}2-6 linked sialic acid on von Willebrand factor specifically enhances proteolysis by ADAMTS13. Blood 2010, 115:2666-2673.
33. McKinnon TA, Chion AC, Millington AJ, Lane DA, Laffan MA. N-linked glycosylation of VWF modulates its interaction with ADAMTS13. Blood 2008, 111:3042-9.
34. Bowen DJ. An influence of ABO blood group on the rate of proteolysis of von Willebrand factor by ADAMTS13. J Thromb Haemost 2003, 1:33-40.
35. Gill JC, Endres-Brooks J, Bauer PJ, Marks WJ, Montgomery RR. The effect of ABO blood group on the diagnosis of von Willebrand disease. Blood 1987, 69:1691-5.
36. Nossent AY, Van Marion V, Van Tilburg NH. von Willebrand factor and its propeptide: the influence of secretion and clearance on protein levels and the risk of venous thrombosis. J Thromb Haemost 2006, 4:2556-62.
37. Haberichter SL, Balistreri M, Christopherson P. Assay of the von Willebrand factor (VWF) propeptide to identify patients with type 1 von Willebrand disease with decreased VWF survival. Blood 2006, 108:3344-51.
38. Gallinaro L, Cattini MG, Sztukowska M. A shorter von Willebrand factor survival in O blood group subjects explains how ABO determinants influence plasma von Willebrand factor. Blood 2008, 111:3540-5.
39. Vlot AJ, Mauser-Bunschoten EP, Zarkova AG. The half-life of infused factor VIII is shorter in hemophiliac patients with blood group O than in those with blood group A. Thromb Haemost 2000, 83:65-9.
40. Fischer K, Pendu R, van Schooten CJ. Models for prediction of factor VIII half-life in severe haemophiliacs: distinct approaches for blood group O and non-O patients. PLoS ONE 2009, 4:e6745.
41. van Schooten CJ, Denis CV, Lisman T. Variations in glycosylation of von Willebrand factor with O-linked sialylated T antigen are associated with its plasma levels. Blood 2007, 109:2430-7.
42. Vasta GR. Roles of galectins in infection. Nat Rev Microbiol 2009, 7:424-38.
43. Crocker PR, Paulson JC, Varki A. Siglecs and their roles in the immune system. Nat Rev Immunol 2007, 7:255-66.
44. Qadura M, Waters B, Burnett E. Recombinant and plasma-derived factor VIII products induce distinct splenic cytokine microenvironments in hemophilia A mice. Blood 2009, 114:871-80.